These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34673218)

  • 1. Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: A network meta-analysis.
    Kiss S; Gede N; Soós A; Hegyi P; Nagy B; Imrei M; Czibere B; Farkas N; Hanák L; Szakács Z; Eröss B; Alizadeh H
    Crit Rev Oncol Hematol; 2021 Dec; 168():103504. PubMed ID: 34673218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials.
    Sekine L; Ziegelmann PK; Manica D; Pithan CDF; Sosnoski M; Morais VD; Falcetta FS; Ribeiro MR; Salazar AP; Ribeiro RA
    Crit Rev Oncol Hematol; 2019 Nov; 143():102-116. PubMed ID: 31563077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
    Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
    Facon T; San-Miguel J; Dimopoulos MA; Mateos MV; Cavo M; van Beekhuizen S; Yuan Z; Mendes J; Lam A; He J; Ammann E; Kumar S
    Adv Ther; 2022 May; 39(5):1976-1992. PubMed ID: 35246820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis.
    Cao Y; Wan N; Liang Z; Xie J; Wang S; Lin T; Zhang T; Jiang J
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e478-e488. PubMed ID: 31130487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis.
    Giri S; Aryal MR; Yu H; Grimshaw A; Pathak R; Huntington SP; Dhakal B
    J Geriatr Oncol; 2020 Nov; 11(8):1285-1292. PubMed ID: 32513568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.
    Michaleas S; Penninga E; Hovgaard D; Dalseg AM; Rosso A; Sarac SB; Jimenez JC; Fernández LL; Fernández CP; Mangas-SanJuan V; Garcia I; Payares-Herrera C; Sancho-López A; Enzmann H; de Castro Lopes Silva MSS; Duarte S; Pignatti F
    Oncologist; 2020 Dec; 25(12):1067-1074. PubMed ID: 33026700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis.
    Ramasamy K; Dhanasiri S; Thom H; Buchanan V; Robinson S; D'Souza VK; Weisel K
    Leuk Lymphoma; 2020 Mar; 61(3):668-679. PubMed ID: 31709875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT).
    Dimopoulos MA; Cavo M; Mateos MV; Facon T; Heeg B; van Beekhuizen S; Gebregergish SB; Nair S; Pisini M; Lam A; Slavcev M
    Leuk Lymphoma; 2020 Mar; 61(3):714-720. PubMed ID: 31686559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis.
    Hungria V; Martínez-Baños DM; Mateos MV; Dimopoulos MA; Cavo M; Heeg B; Garcia A; Lam A; Machnicki G; He J; Fernandez M
    Adv Ther; 2020 Dec; 37(12):4996-5009. PubMed ID: 33067698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
    Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
    J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study.
    Lee JY; Park SS; Jeon YW; Shin SH; Yahng SA; Min CK;
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11907-11918. PubMed ID: 37418057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.
    Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Knop S; Doyen C; Lucio P; Nagy Z; Pour L; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Yoon SS; Iosava G; Fujisaki T; Garg M; Iida S; Bladé J; Ukropec J; Pei H; Van Rampelbergh R; Kudva A; Qi M; San-Miguel J
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):785-798. PubMed ID: 34344638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Network meta-analysis of first-line treatments in transplant-ineligible multiple myeloma patients.
    Gil-Sierra MD; Gimeno-Ballester V; Fenix-Caballero S; Alegre-Del Rey EJ
    Eur J Haematol; 2020 Jul; 105(1):56-65. PubMed ID: 32145104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
    Chari A; Rodriguez-Otero P; McCarthy H; Suzuki K; Hungria V; Sureda Balari A; Perrot A; Hulin C; Magen H; Iida S; Maisnar V; Karlin L; Pour L; Parasrampuria DA; Masterson T; Kosh M; Yang S; Delioukina M; Qi M; Carson R; Touzeau C
    Br J Haematol; 2021 Mar; 192(5):869-878. PubMed ID: 33216361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
    Larocca A; Mina R; Offidani M; Liberati AM; Ledda A; Patriarca F; Evangelista A; Spada S; Benevolo G; Oddolo D; Innao V; Cangiolosi C; Bernardini A; Musto P; Amico V; Fraticelli V; Paris L; Giuliani N; Falcone AP; Zambello R; De Paoli L; Romano A; Palumbo A; Montefusco V; Hájek R; Boccadoro M; Bringhen S
    Haematologica; 2020 Apr; 105(4):1074-1080. PubMed ID: 31248973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis.
    Blommestein HM; van Beurden-Tan CHY; Franken MG; Uyl-de Groot CA; Sonneveld P; Zweegman S
    Haematologica; 2019 May; 104(5):1026-1035. PubMed ID: 30606791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database.
    Jimenez-Zepeda VH; Venner C; McCurdy A; Masih-Khan E; Atenafu EG; Sebag M; Stakiw J; Song K; LeBlanc R; Reiman T; Louzada M; Kotb R; Gul E; Reece D
    Br J Haematol; 2021 May; 193(3):532-541. PubMed ID: 33559897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.